The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19


Autor: Xuedong An et al.


Journal: Chinese Medicine volume 16, Article number: 44 (2021), englisch


The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), first broke out in Wuhan, China, in 2019. SARS-CoV-2 develops many types of mutations (such as B.1.1.7), making diagnosis and treatment challenging. Although we now have a preliminary understanding of COVID-19, including pathological changes, clinical manifestations, and treatment measures, we also face new difficulties.

The biggest problem is that most COVID-19 patients might face sequelae (e.g., fatigue, sleep disturbance, pulmonary fibrosis) during the recovery phase. We aimed to test six Chinese patent medicines to treat three major abnormal symptoms in COVID-19 patients during the recovery phase, including cardiopulmonary function, sleep disturbance, and digestive function. We launched the “three syndromes and six Chinese patent medicines” randomized, double-blind, placebo-controlled, multicenter clinical trial on April 10, 2020.

The results showed that Jinshuibao tablets and Shengmaiyin oral liquid significantly improved the cardiopulmonary function of recovering COVID-19 patients. Shumian capsules, but not Xiaoyao capsules, significantly improved patients’ sleep disorders. This might be because the indication of Xiaoyao capsules is liver qi stagnation rather than psychological or emotional problems. Xiangsha Liujun pills and Ludangshen oral liquid significantly improved digestive function. Our research provides a guideline for treating COVID-19 sequelae in patients during the recovery period based on high-quality evidence.


Andere Benutzer haben sich neben diesem auch noch folgende Artikel angesehen:

Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
Jeffrey E Gold et al.; 2021

Research Progress of Traditional Chinese and Western Medicine on Polycystic Ovary Syndrome
Lu Zhang et al; 2021

What's the choice for goji: Lycium barbarum L. or L. chinense Mill.?
RuyuYao et al.; 2021




 
 

Vorheriger Artikel

Übersicht

Nächster Artikel
 

Link zum Journal